We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Identification of Sentinel Lymph Nodes With Methylene Blue and Isotope

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00314405
First Posted: April 13, 2006
Last Update Posted: August 8, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospital, Strasbourg, France
  Purpose
The aim of this study is to evaluate the performance of a double labelling method using isotope and methylene blue dye injection to localize precisely Sentinel Lymph Node (SLN) in a series of 100 patients with infiltrative breast cancer justifying SLN excision. Method and patients: SLN excision will be performed on 100 patients treated for infiltrative breast cancer. After preoperative methylene blue dye injection and lymphoscintigraphy, individual localization of the radioactive and stained nodes will be performed. After the surgery, SLN will be submitted to serial analysis and immunohistochemistry. A comparison of the two methods and an economical evaluation of the complete procedure will be performed.

Condition Intervention
Infiltrative Breast Cancer Drug: Methylene blue (1%) Drug: Rhenium sulfure Procedure: Surgical procedure Procedure: Anatomo-pathologic procedure

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Identification of Sentinel Lymph Node (SLN) in Breast Cancer Care: Clinical and Economical Evaluation of a Double Method Using Isotope and Methylene Blue Dye Injection.

Resource links provided by NLM:


Further study details as provided by University Hospital, Strasbourg, France:

Primary Outcome Measures:
  • Determination of an optimized protocol for SLN identification, with a double method using isotope and methylene blue dye injection.

Secondary Outcome Measures:
  • Comparison of the results of SLN serial sectioning, with H&E and IHC staining
  • Economical evaluation of SLN procedure.

Estimated Enrollment: 100
Study Start Date: April 2006
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with infiltrative breast cancer (diagnosed pre-operatively by core biopsy)
  • approval and informed consent

Exclusion Criteria:

  • chemotherapy
  • locoregional radiotherapy
  • prevalent axillary lymph node
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00314405


Locations
France
Service de Gynécologie-Obstétrique, Hôpital Civil
Strasbourg, France, 67091
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Study Director: Jean-Pierre Bellocq, MD Hôpitaux Universitaires de Strasbourg
  More Information

ClinicalTrials.gov Identifier: NCT00314405     History of Changes
Other Study ID Numbers: 3157
First Submitted: April 11, 2006
First Posted: April 13, 2006
Last Update Posted: August 8, 2008
Last Verified: February 2008

Keywords provided by University Hospital, Strasbourg, France:
sentinel lymph node
SLN
probe
breast cancer
lymphoscintigraphy
methylene blue dye

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Methylene Blue
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action